Merck kick-starts PhIII cholesterol trials for its oral PCSK9; Baxter recalls 13,000+ vials of chemotherapy
Merck revealed Friday it started up its first late-stage clinical program for an oral PCSK9 inhibitor for cholesterol.
The program is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
